Late cardiac effect of anthracycline therapy in physically active breast cancer survivors - a prospective study

Nagy, AC ✉ [Nagy, András Csaba (kardiológia), szerző] Uzsoki Utcai Kórház; GulAcsi-BArdos, P [Gulácsi-Bárdos, Petra (Belgyógyászat-kar...), szerző] Uzsoki Utcai Kórház; CserEp, Z [Cserép, Zsuzsanna (belgyógyászat), szerző] Uzsoki Utcai Kórház; Hangody, L [Hangody, László (Porcfelszínképzés), szerző] Uzsoki Utcai Kórház; Semmelweis Egyetem; Traumatológiai Tanszék (SE / AOK / K); Forster, T [Forster, Tamás (Kardiológia), szerző] II. sz. Belgyógyászati Klinika és Kardiológiai ... (SZTE / ÁOK)

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: NEOPLASMA 0028-2685 64 (1) pp. 92-100 2017
  • SJR Scopus - Cancer Research: Q3
    The late-onset cardiotoxic effect of anthracycline is known, however the early detection and prevention of subclinical myocardial damage has not been fully understood yet. Besides medical therapy regular physical activities may also play a role in the prevention and reduction of side effects of chemotherapy. The aim of our present study was to detect the effect of regular physical activities on the diastolic function and on the symptoms of late heart failure in case of anthracycline chemotherapy. The prospective study included 55 female patients (age 31-65 year, average 49.5 years) with breast cancer and no cardiovascular risk factors. Proper cardiologic checkup included physical examination (blood pressure, pulse, etc.), ECG, standard echocardiography parameters (EF, LV dimensions etc.) and specific tissue Doppler (TDI) measurements. Symptoms of heart failure were also recorded. After five years of follow-up, symptoms of heart failure were evaluated again. Patients were assigned into two groups depending on their physical activity: 36 patients did perform regular physical activities (mean age 49.2 years) and 19 patients did not (average age 50.1 years). There was no significant difference between the two groups in basic physiological or standard echocardiography parameters neither at the baseline nor at the later time points. Diastolic dysfunction (decreased E/A) was detected 6 months after the beginning of the treatment (T2 time point) in both groups. In the inactive group this value fell below one however there was no significant difference (1.1+/-0.25 vs. 0.95+/-0.22). One year after the beginning of the treatment (T3) a significant difference could be detected between the two groups (1.05+/-0.28 vs. 0.86+/-0.25. P=0.038). Consistent change in diastolic function (Ea/Aa) could be detected with the more sensitive TDI (Tissue Doppler Imaging) measurements after treatments in both groups, especially in the septal segment (in the non active group the Ea/Aa decreased markedly but not significantly at T2 - 1.1+/-0.55 vs. 0.81+/-0.44, and this difference became significant at T3 and 2 years after treatment (T4), p=0.007 and p=0.065). The filling pressure (E/Ea) rose above 10 (p=0.09) in the non active group at T2; and it kept rising in both groups and became significant at T3 (p=0.012). Five years after the onset of the treatment symptoms of heart failure were less frequently reported in the physically active group than in the inactive one (19.45% vs. 68.42%). The data of our study show that the diastolic dysfunction of the left ventricle related to the anthracycline therapy became evident in the physically active group later and the symptoms of heart failure were less frequent than in the non active group after five years period. Enrollment in sport activities could be a good means for partial prevention in this group of patients. Cardiologic checkup at proper intervals plays a pivotal role in detection of possible cardiotoxicity. This is a strong indication for changes in the lifestyle of the patient and the treatment protocol alike.
    Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
    2020-12-05 05:48